Adding to the list of BCR::ABL1-dependent and -independent treatment modalities for BP-CML patients, we expect our discovery of novel therapeutic strategies targeting FLT3-JAK/STAT3-TAZ-TEAD-CD36 signaling to contribute to the effective prediction and treatment of CML. Here, CD36 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.